Invention Grant
- Patent Title: Methods for treatment with bucindolol based on genetic targeting
- Patent Title (中): 基于遗传靶向的布可洛尔治疗方法
-
Application No.: US11838142Application Date: 2007-08-13
-
Publication No.: US08093286B2Publication Date: 2012-01-10
- Inventor: Stephen B. Liggett , Michael Bristow
- Applicant: Stephen B. Liggett , Michael Bristow
- Applicant Address: US CO Denver
- Assignee: The Regents of the University of Colorado, a body corporate
- Current Assignee: The Regents of the University of Colorado, a body corporate
- Current Assignee Address: US CO Denver
- Agency: Fulbright & Jaworski L.L.P.
- Main IPC: A61K31/405
- IPC: A61K31/405 ; A61K47/00 ; A61P43/00 ; C12Q1/68 ; C07H21/02 ; C07H21/04 ; G01N33/53
Abstract:
The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the β1-adrenergic receptor (AR).
Public/Granted literature
- US20080227844A1 Methods for Treatment with Bucindolol Based on Genetic Targeting Public/Granted day:2008-09-18
Information query
IPC分类:
